News

Tycel Phillips, MD, a clinical associate professor of hematology and medical oncology at the University of Michigan Health, discusses the mechanism of action of glofitamab in patients with mantle cell lymphoma.

The FDA closed 2021 with 5 new treatment options for cancer and multiple designations that may bring new therapies to the armamentarium for oncologists in the future.

Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.

An application for FDA approval has been filed for teclistamab as a potential treatment for patients with relapsed or refractory multiple myeloma.

A novel natural killer cell therapy is now on the fast track to FDA approval and being assessed in a phase 1 clinical trial.

In the community setting, brexucabtagene autoleucel shows efficacy in patients with relapsed/refractory mantle cell lymphoma.

A phase 2 study is underway to determine the efficacy and safety of selinexor in patients with myelofibrosis.

Darren R. Feldman, MD, discusses the standard of care for the treatment of testicular cancer.

Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

As part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, discussed unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation. He also explained how to approach the treatment of patients with challenging non-clear cell tumors.

HER2 mutations are a major clinical biomarker in breast cancer. However, overcoming drug resistance remains a key clinical obstacle.

In an interview with Targeted Oncology, Toni Choueiri, MD, discusses the impact the approval of adjuvant pembrolizumab has had on the RCC space.

Cristiane D. Bergerot, PhD, discussed factors contributing to financial toxicity in patients with RCC and how it impacts oncology care providers.

A phase 2 study of surufatinib in patients with biliary tract carcinoma showed some benefit and a larger phase 3 study is underway.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Andrea Holowatyj, PhD, MSCI delved into the growing issue of early-onset appendiceal cancer, how it impacts certain groups, and what efforts can improve outcomes for these patients in the future.

FDA approval is being sought for dovitinib as a treatment option for patients with renal cell carcinoma.

Results from the phase 3 JUPITER-02 trial show that oncologists can extend progression-free survival in patients with nasopharyngeal carcinoma by adding toripalimab to chemotherapy.

Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.

Annelise Wilhite, MD, a gynecology oncology fellow at the University of South Alabama Health, discusses the difficulty in treating vulvar and vaginal melanomas.

Rana R. McKay, MD, discussed the implications of the KEYNOTE-564 study along with the future of adjuvant immunotherapy in RCC, in an interview with Targeted Oncology

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies.

The FDA’s orphan drug designation granted to silmitasertib for medulloblastoma marks the agent’s second such designation.

Ruben Niesvizky, MD, discusses the shift in standard of care treatment for multiple myeloma.

Early research shows that the menin inhibitor, KO-539, may have synergy with other targeted agents for the treatment of KMT2A-rearranged and NPM1-mutated acute myeloid leukemia tumors.

Entospletinib in combination with chemotherapy will be evaluated in the phase 3 AGILITY study in patients with NPM1-mutated AML.

In patients with EGFR-positive non–small cell lung cancer who develop a T790M mutation after disease progression, chemo-antiangiogenesis may prove beneficial.

Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.